Gradient Release Drug Composite Nanofibrous Membrane Designed for Preventing Tumor Recurrence and Repair of Postoperative Bladder Cancer Defect

Bladder tumor is the most common tumor in urology. Tumor resection as a conventional therapy is usually used in the clinical treatment. However, the electric incision wound produced during the operation is generally deep into the muscle layer. In addition, the multiple tumors and the large wound sites will bring complications. These outcomes increase the pain IP: 203.8 109.20 On Wed, 03 May 2023 10:21 50 Copy ight A e ica Scie t fic Publishe s and the economic burden of patients. Herein, a composite nanofibers-drug release system (CNFs-DRS) was designed Delivered by Ingenta based on the various degradable nanofibers. The experimental results show that the prepared CNFs-DRS exhibits good biocompatibility, and the anti-tumor drugs (pirarubicin) carried by the first layer are released rapidly within 2-4 h with the ability to kill tumor cells. The second layer consists of slow-degrading material and basic fibroblast growth factor (bFGF), which shows a long-term and stable release, and promotes the proliferation of smooth muscle cells and the proliferation of urine-derived stem cells (USCs). The third layer (PLLA layer) can maintain the morphology of the composite membrane. The obtained CNFs-DRS can replace and simplify the clinical operation of bladder chemical drug perfusion within 24 h after operation, immediately kill the residual tumor cells in the bladder, and support and repair the wound after tumor resection.